What are the routes of administration for calcitonin and what is the maximum recommended adult dose?

Calcitonin Routes of Administration and Maximum Dose

Calcitonin is administered via intranasal spray at 200 IU daily (alternating nostrils) for osteoporosis, or via subcutaneous/intramuscular injection at 80–160 units/day (or 4 IU/kg every 12 hours) for severe hypercalcemia, with treatment limited to 48–72 hours in acute hypercalcemia due to universal tachyphylaxis. 1, 2, 3

Routes of Administration

Intranasal (Nasal Spray)

• Approved for postmenopausal osteoporosis only, administered as 1 spray (200 IU) per day, alternating nostrils daily. 1
• The nasal formulation should be reserved for patients who cannot tolerate bisphosphonates, denosumab, estrogen, selective estrogen response modulators, tibolone, or anabolic agents. 4
• Important safety concern: The European Medicines Agency and Health Canada have withdrawn nasal calcitonin from the market due to increased risk of prostate, liver, and other malignancies, though the pathophysiologic basis remains unclear. 4

Subcutaneous or Intramuscular Injection

• Used for acute severe hypercalcemia (corrected calcium ≥ 14 mg/dL or ≥ 3.5 mmol/L) as adjunctive therapy with bisphosphonates or denosumab. 2, 5, 3
• Dosing: 80–160 units/day or 4 IU/kg every 12 hours subcutaneously or intramuscularly. 5, 3
• Onset of action occurs within 2–4 hours, with peak effect at 24–48 hours. 5, 3

Oral Formulation (Not FDA-Approved)

• Oral calcitonin formulations using drug-delivery carriers (e.g., 5-CNAC) have been investigated but failed to meet key endpoints in Phase III trials for postmenopausal osteoporosis and osteoarthritis. 6, 7
• Oral bisphosphonates (alendronate, risedronate) are ineffective for acute hypercalcemia and should never be used for this indication. 8

Maximum Dose and Duration

For Severe Hypercalcemia

• Maximum dose: 160 units/day (or 4 IU/kg every 12 hours) subcutaneously or intramuscularly. 5, 3
• Critical duration limit: Treatment must be restricted to 48–72 hours because universal tachyphylaxis develops, eliminating further benefit. 2, 5, 3
• The bisphosphonate or denosumab must be continued beyond 72 hours to maintain calcium control after calcitonin is stopped. 5, 3

For Osteoporosis (Nasal Spray)

• Standard dose: 200 IU/day intranasally (one spray per nostril, alternating daily). 1
• Higher doses (400 IU/day) and lower doses (100 IU/day) did not demonstrate superior efficacy for vertebral fracture reduction in the PROOF trial; only the 200 IU dose showed a 33% reduction in vertebral fracture risk. 4, 9, 10
• Single doses up to 1600 IU, doses up to 800 IU/day for 3 days, and chronic administration up to 600 IU/day have been studied without serious adverse effects. 1

Clinical Context and Algorithmic Approach

When to Use Injectable Calcitonin

• Indication: Severe hypercalcemia of malignancy (calcium ≥ 14 mg/dL or ≥ 3.5 mmol/L) requiring rapid calcium reduction. 2, 5, 3
• Always combine with IV bisphosphonate (zoledronic acid 4 mg over 15 min or pamidronate 90 mg over 2 h) or denosumab 120 mg subcutaneously. 2, 5, 3
• Timing: Administer calcitonin immediately alongside the anti-resorptive agent; do not delay. 5, 3
• Stop at 48–72 hours: Continue only the bisphosphonate or denosumab thereafter. 2, 5, 3

When to Use Nasal Calcitonin

• Indication: Postmenopausal osteoporosis in women >5 years postmenopause who cannot tolerate or refuse first-line therapies (bisphosphonates, denosumab, hormone therapy, anabolic agents). 1, 4
• Fracture efficacy: Reduces vertebral fractures by 33% at 200 IU/day but has no proven effect on hip or nonvertebral fractures. 4, 9, 10
• Supplementation required: All patients must receive at least 1000 mg elemental calcium and 400 IU vitamin D daily. 1
• Re-evaluate periodically: Due to malignancy concerns, the need for continued therapy should be reassessed regularly. 1

Critical Pitfalls to Avoid

• Never continue calcitonin beyond 72 hours in hypercalcemia management; tachyphylaxis eliminates benefit and wastes resources. 2, 5, 3
• Never use oral bisphosphonates (alendronate, risedronate) for acute hypercalcemia; they are ineffective and delay appropriate treatment. 8
• Never use calcitonin monotherapy for hypercalcemia of malignancy; it must be combined with a bisphosphonate or denosumab. 2, 5, 3
• Do not prime the nasal pump before each daily dose; prime only once before the first use. 1
• Avoid nasal calcitonin as first-line therapy for osteoporosis given malignancy concerns and superior alternatives. 4, 1
• Ensure adequate calcium and vitamin D before and during calcitonin therapy to prevent hypocalcemia, especially when combined with denosumab. 5, 3, 1